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Key points 
1.  We addressed the hypothesis that the heterocyclic aldehyde 5-hydroxymethyl-2-furfural (5HMF) 
may act synergistically to ameliorate the complications of sickle cell disease through effects on red 
blood cell (RBC) membrane transport, in addition to its well-known action of increasing the oxygen 
affinity of HbS. 
2.  5HMF was found to reduce deoxygenation-induced dehydration of RBCs, whether in response to 
maintained deoxygenation or cyclical deoxygenation / re-oxygenation. 
3.  Acting at low millimolar concentrations, 5HMF reduced the activity of the deoxygenation-induced 
cation conductance (sometimes termed Psickle), an effect which correlated with reduction in sickling.  
5HMF similarly inhibited deoxygenation-induced activation of the Ca2+-activated K+ channel (or 
Gardos channel), an effect not seen following pharmacologically-mediated increases in intracellular 
Ca2+ via the ionophore A23187.  Deoxygenation-induced phosphatidylserine exposure, which is 
associated with Ca2+ entry via Psickle, was also inhibited by 5HMF 
4.  By contrast, effects of 5HMF on the K+-Cl- cotransporter (KCC) were modest, with slight inhibition 
following treatment with N-ethylmaleimide (NEM) to abolish activity of its regulatory protein 
kinases, but stimulation in RBCs untreated with NEM. 
5.  It would therefore appear that an important beneficial action of 5HMF, in addition to effects on 
HbS oxygen affinity, is reduction in Psickle-mediated Ca
2+ entry following RBC sickling, thereby 
inhibiting the deleterious sequelae of Gardos channel activation, RBC dehydration and also lipid 
scrambling.
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Abstract 
The heterocyclic aldehyde 5-hydroxymethyl-2-furfural (5HMF) interacts allosterically with HbS in red 
blood cells (RBCs) from patients with sickle cell disease (SCD), thereby increasing oxygen affinity and 
decreasing HbS polymerisation and RBC sickling during hypoxia.  We hypothesise that should 5HMF 
also inhibit the main cation pathways implicated in dehydration of RBCs from SCD patients - the 
deoxygenation-induced cation pathway (Psickle), the Ca
2+-activated K+ channel (the Gardos channel) 
and the K+-Cl- cotransporter (KCC) - it would have a synergistic effect in protection against sickling, 
directly through interacting with HbS, and indirectly through maintaining hydration and reducing 
[HbS].  This study was therefore designed to investigate the effects of 5HMF on RBC volume and K+ 
permeability in vitro.  5HMF markedly reduced the deoxygenation-induced dehydration of RBCs 
whether in response to maintained deoxygenation or to cyclical deoxygenation / re-oxygenation.  
5HMF was found to inhibit Psickle, an effect which correlated with its effects on sickling.  
Deoxygenation-induced activation of the Gardos channel and exposure of phosphatidylserine were 
also inhibited, probably indirectly via reduced entry of Ca2+ through the Psickle pathway.  Effects of 
5HMF on KCC were more modest with a slight inhibition in N-ethylmaleimide (NEM, 1 mM) -treated 
RBCs and stimulation in RBCs untreated with NEM.  These findings support the hypothesis that 
5HMF may also be beneficial through effects on RBC ion and water homeostasis. 
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Introduction 
The complications of sickle cell disease (SCD) originate from the presence and polymerisation of the 
abnormal form of haemoglobin (Hb), HbS, in patients’ red blood cells (RBCs).  Compared to the 
normal adult HbA, HbS shows a single amino acid substitution at the β6 position, whereby glutamic 
acid is replaced by valine (Perutz & Mitchison 1950; Bunn & Forget 1986).  Following the 
deoxygenation-induced conformational change of Hb, the loss of these negative charges allows 
neighbouring HbS molecules to aggregate and form long, rigid polymers which distort RBC shape.  
Other deleterious sequelae include altered rheology, RBC fragility, solute loss and dehydration and 
increased stickiness (Bunn & Forget 1986).  The consequent clinical complications fall into two 
groups:  first, a chronic anaemia consequent upon increased red blood cell (RBC) destruction;  and 
second, acute ischaemic signs following blockage of the microvasculature (Steinberg 1999; Nagel & 
Platt 2001; Rees et al. 2010).  The precise clinical signs depend on the organ(s) involved but can be 
numerous.  Severity varies markedly between individuals, however, though the reason for this is not 
understood (Steinberg 1999).  
There is at present no specific treatment for SCD (Steinberg 1999; Rees et al. 2010) although 
hydroxyurea has received considerable attention (Charache et al. 1987; Charache et al. 1992; Platt 
2008; Rees 2011).  The mechanisms of action of hydroxyurea remain uncertain but are probably 
mostly due to increased expression of fetal Hb, HbF.  As HbF is not incorporated into HbS polymers 
and also serves to dilute the intracellular concentration of HbS, its expression reduces the tendency 
for HbS to polymerise and for HbS-containing RBCs to sickle.  Hydroxyurea, however, is not without 
risks, being potentially teratogenic especially in the long term, showing variable response between 
individuals, and also having problems with non-compliance (Platt 2008).  Such factors have restricted 
its use to more severely affected individuals (Rees 2011).   
Investigations continue into the development of other effective therapies.  A promising alternative 
approach has been the development of compounds which directly interpolate with the HbS 
molecules and thereby reduce polymerisation upon deoxygenation.  The most encouraging of these 
have been the aromatic aldehydes such as vanillin (Zaugg et al. 1977; Abraham et al. 1991; 
Abdulmalik et al. 2005) and similar substituted benzaldehydes like 12C79 (valerosol) and 589C80 
(tucaresol) (Kneen & White 1981; Beddell et al. 1984).  These aldehydes form Schiff bases with HbS, 
allosterically increasing its oxygen affinity, and reducing polymerisation and RBC sickling.  Despite 
effectively reducing sickling and increasing RBC hydration, none of these compounds proved useful 
clinically (eg Fitzharris et al. 1985; Keidan et al. 1986; Arya et al. 1996).  More recently naturally 
occurring heterocyclic derivatives of furanic acid have been tested (Safo et al. 2004; Abdulmalik et 
al. 2005).  These are active at lower concentrations and appear better tolerated.  One of them, 5-
hydroxymethyl-2-furfural (5HMF, also known as Aes-103), is currently in phase two clinical trials in 
SCD patients in USA and UK (NIH 2013). 
Several abnormal, or abnormally regulated, cation transporters participate in the pathogenesis of 
SCD (Joiner 1993; Gibson & Ellory 2002; Lew & Bookchin 2005).  These include the well-established 
pathways of the K+-Cl- cotransporter (or KCC) and the Ca2+-activated K+ channel (or Gardos channel), 
together with a third pathway, sometimes termed Psickle.  Unlike KCC and the Gardos channel, the 
molecular identity of Psickle is unknown but it appears to be a cation conductance pathway activated 
by deoxygenation, HbS polymerisation and RBC shape change (Joiner et al. 1988; Joiner 1993; Ma et 
al. 2012).  Psickle mediates both entry of Ca
2+ (Rhoda et al. 1990; Etzion et al. 1993) and exit of Mg2+ 
(Ortiz et al. 1990; Willcocks et al. 2002), with subsequent activation of the Gardos channel and also 
perhaps KCC.  Deoxygenation-induced Ca2+ entry through Psickle is further implicated in loss of 
phosphatidylserine (PS) asymmetry in RBCs from SCD patients (Lubin et al. 1981; Blumenfeld et al. 
1991; Kuypers 1998; de Jong et al. 2001; Weiss et al. 2012; Cytlak et al. 2013), subsequent to 
activation of a Ca2+-dependent scrambling process (Haest 2003).   
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Together the three cation pathways interact to mediate solute loss (Gibson 2001; Lew & Bookchin 
2005), thereby concentrating HbS, which greatly reduces the lag time for polymerisation upon 
deoxygenation (Eaton & Hofrichter 1987).  PS exposure also increases RBC stickiness (Kuypers 2008).  
These processes thereby increase the likelihood of sickling and vascular occlusion of the 
microvasculature. 
Through its effects on HbS polymerisation, it is possible that 5HMF also modulates the cation 
permeability of RBCs from SCD patients.  Should 5HMF reduce solute loss and maintain better 
hydration of the RBCs, HbS polymerisation would be inhibited by two potentially synergistic 
mechanisms – a direct interaction of 5HMF with HbS stabilising the oxygenated conformation, and a 
second mechanism through reduction in [HbS] thus increasing the lag time to sickling on 
deoxygenation.  This hypothesis is investigated in the present study.  Findings show that RBC volume 
is better preserved in response to maintained deoxygenation and also to cyclical deoxygenation / re-
oxygenation.  Radioactive tracer methodologies were used to investigate the effects of 5HMF on K+ 
permeability, and specifically the activities of Psickle, the Gardos channel and KCC in RBCs from SCD 
patients.  FITC-labelled lactadherin was also used to measure PS exposure.  Results show that 5HMF 
modulates all three cation transport pathways and PS scrambling, as well as affecting HbS 
polymerisation and sickling.  These additional actions of 5HMF may be of significant consideration 
when assessing its clinical use and also in the design of similar more efficacious compounds to 
ameliorate the complications of SCD.
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Materials and methods 
Chemicals 
Bumetanide, 5-hydroxymethyl-2-furfural (5HMF), 3-[N-morpholino] propane sulfonic acid (MOPS), N-
ethylmaleimide (NEM), ouabain and salts were purchased from Sigma Chemical Co. (Poole, Dorset, 
UK).  Clotrimazole and A23187 were purchased from Calbiochem (Nottingham, UK).  86Rb+ was 
supplied by Perkin Elmer (Beaconsfield, UK).  Fluorescein isothiocyanate-conjugated lactadherin (LA-
FITC) came from Haematologic Technologies Inc. (VT, USA) supplied via Cambridge Bioscience 
(Cambridge, UK) and phycoerythrin (PE)-conjugated anti-glycophorin A from Becton Dickinson 
Biosciences (CA, USA). 
 
Sample collection and handling 
Blood samples were taken for routine tests according to clinical indications, from patients 
homozygous (HbSS) for sickle cell disease (SCD) into the anticoagulant EDTA.  Once routine testing 
had been completed, discarded, anonymised blood was analysed.  The use of discarded blood was 
approved by the local ethics committee following guidelines set out in the Declaration of Helsinki.  
Samples were kept at 4 oC until use within 48 h. 
 
Solutions and tonometry 
The standard saline (Cl-MBS) comprised (in mM):  145 NaCl, 1.1 CaCl2, 5 glucose and 10 MOPS, (pH 
7.4 at 37 oC; 290  5 mosmol.kg-1 H2O).  For experiments in which Cl
- dependence of K+ influx was 
examined, NO3
--containing salts replaced those containing Cl- (N-MBS).  To prevent the rapid RBC 
shrinkage which would otherwise occur following maximal stimulation of the Gardos channel in 
experiments in which intracellular Ca2+ was directly raised by incubation with the Ca2+ ionophore 
A23187, a high-K+- and low-Ca2+-containing saline was used with Ca2+ buffered with EGTA, 
comprising (in mM):  80 KCl, 70 NaCl, 2 CaCl2, 0.15 MgCl2, 2 EGTA, 5 glucose and 10 MOPS (HK-MBS) 
with a free [Ca2+]o of 10 µM.  The wash solution to remove unincorporated 
86Rb+ comprised isotonic 
MgCl2 (107 mM), buffered with MOPS (10 mM), pH 7.4 at 4 
oC (Mg-MBS).  Stock solutions of 
bumetanide (10 mM) were prepared in 100 mM Tris base and used at a final concentration of 10 
M.  Stock solutions of ouabain (10 mM) were prepared in distilled water and used at a final 
concentration of 100 M.  Stocks of clotrimazole (CLT;  5 mM) were prepared in DMSO and used at a 
final concentration of 5 μM.  In most experiments, whole blood was washed five-times in N-MBS to 
remove Cl-, plasma and buffy coat.  RBC suspensions were then pre-incubated at 15 % haematocrit 
(Hct) in eppendorf tubes with or without 5HMF (5 mM) for 30 min at 37 oC and then placed in 
tonometers (Eschweiler, Kiel, Germany) to equilibrate at the requisite O2 tension before flux 
measurement (still in N-MBS).  Tonometers were flushed with warm, humidified gas mixtures, 
supplied at the appropriate O2 tension using a Wösthoff gas mixing pump (Speake et al. 1997).  For 
flux measurements, RBC suspensions were then diluted 10-fold into flux tubes, still equilibrated at 
the required O2 tension.  Where its effects were investigated, tonometers and flux tubes also 
contained 0.1-5 mM 5HMF.  For experiments involving A23187, the ionophore (6 µM final) was 
added to warm saline at 37 oC in test tubes whilst vortexing.  For experiments involving NEM, NEM 
(1 mM) was present during pre-incubation with 5HMF after which aliquots were again diluted 10-
fold into flux tubes.  For CLT, dissolved in DMSO, appropriate controls were all treated with the same 
concentration of solvent (0.1 % final).   
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Measurements of RBC sickling 
To assess morphological sickling, RBCs were incubated in tonometers at 2 % Hct for 20 min after 
which samples were fixed in the same solution as that used during incubation but with the addition 
of 0.3 % glutaraldehyde.  Control experiments showed that this protocol was sufficient to maintain 
RBC shape for several weeks.  Sickling was assessed by light microscopy.  Several hundred RBCs 
(typically 300-400) were counted using an Improved Neubauer haemocytometer.  Control 
experiments examined the effect of 5HMF (5 mM) on sickling at an O2 tension of 10 mmHg.  These 
showed that the action of 5HMF was not immediate but that some pre-incubation was required, 
probably due to the time taken for aldehydes like 5HMF to enter RBCs and form adducts with Hb 
(Abraham et al. 1991; Abdulmalik et al. 2005).  Thus in a representative experiment at 10 mmHg O2, 
inhibition of sickling by 5HMF over 20 min was 20 % without pre-inucbation, increasing to inhibitions 
of 47 %, 68 %, 71 % and 79 % after 15, 30, 45 and 60 min pre-incubation.  In subsequent 
experiments, 5HMF was therefore added to RBC suspensions at 37 oC for 30 min prior to flux and 
volume assays, and 60 min where phosphatidylserine exposure was measured. 
 
Measurement of RBC water content 
The effect of different oxygen tensions (with RBCs maintained under full oxygenation or 
deoxygenated at 0 or 15 mmHg O2, or during cyclical deoxygenation / re-oxygenation), all for 60 min 
at 37 oC, was investigated on RBC volume.  For oxy / deoxy cycles, gas delivered by the Wösthoff 
pump was switched between an oxygen tension of 0 and 100 mmHg every 10 min.  RBC water 
content was then measured by the wet weight – dry weight method (Borgese et al. 1991).  In brief, 
after incubation for 60 min at 5 % Hct, RBCs were pelletted by centrifugation at 12,000 g for 15 min 
at 4 oC.  The extruded pellet was weighed immediately (to an accuracy of 0.01 mg) and again after 
drying for 18 h at 95 oC.  Water content was expressed as ml water per g dry cell solids (ml / g d.c.s.). 
 
K+ flux measurements 
To determine the activity of the K+ transport pathways, K+ influx was measured at 37 oC using 86Rb+ 
as a congener for K+ (Dunham & Ellory 1981; Hannemann et al. 2011).  RBCs washed in N-MBS were 
equilibrated in tonometers for 20 min then diluted 10-fold into saline, pre-equilibrated at the 
appropriate O2 tension, at 260 mOsm.kg
-1 and pH 7.  Hypotonic swelling and low pH were chosen in 
order to stimulate the K+-Cl- cotransporter (KCC).  86Rb+ was added in 150 mM KNO3 to give a final 
[K+] of 7.5 mM in all experiments except those with HK saline and A23187-treated RBCs.  Typically, 
three flux conditions were used:  (i) Cl-MBS, (ii) Cl-MBS with clotrimazole and (iii) N-MBS with 
clotrimazole.  After incubation with radioisotope for 10 min, RBCs were washed five-times in ice-cold 
Mg-MBS to remove extracellular 86Rb+.  Ouabain (100 M) and bumetanide (10 M) were present in 
all experiments to obviate any K+ transport through the Na+/K+ pump and the Na+-K+-2Cl- 
cotransporter, respectively.  KCC activity was assayed as Cl--dependent K+ influx (using flux 
conditions ii & iii);  Gardos channel activity as the CLT-sensitive (5 μM) K+ influx (using conditions i & 
ii);  and Psickle as the deoxygenation-induced, clotrimazole-independent K
+ influx measured in the 
absence of Cl- (condition iii).  When measuring Gardos channel activity in the presence of A23187, a 
K+ uptake measurement was carried out with serial samples of RBCs taken at 1, 3, 5, 7 and 10 min 
after addition of 86Rb+, with aliquots added directly into ice-cold Mg-MBS and then washed a further 
four times.  Either microhaematocrit determination or the cyanohaemoglobin method was used to 
measure the Hct with appropriate samples for this taken before the start of each experiment. 
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Labelling of phosphatidylserine exposure 
To investigate the effect of 5HMF on deoxygenation-induced phosphatidylserine (PS) exposure, RBC 
suspensions (0.5 % Hct) were placed in a 24-well plate (Nunclon) in Cl-MBS with 1 mM vanadate, and 
continuously shaken at 270 rpm in a hypoxic Galaxy R incubator (Model 300, RS Biotech, CandM 
Scientific Ltd, Livingston, UK) for up to 4 hours.  Oxygen tension was set to 20 mmHg.  To measure PS 
exposure, 5 µl aliquots (105 RBCs) of each sample were placed in 250 µl of LA-FITC binding buffer (16 
nM LA-FITC in standard saline with 1 mM vanadate) and incubated in the dark at room temperature 
for 10 min.  RBCs were then pelleted by centrifugation for 10 s at 16,100 g, washed once in saline to 
remove unbound LA-FITC and kept on ice until flow cytometry analysis.  Control unlabelled RBCs 
treated with 5HMF (5 mM) established the absence of aldehyde-dependent self-fluorescence. 
 
FACS acquisition and analysis 
Externalised PS was measured with FITC using an excitation wavelength of 488nm in the FL1 channel 
with an emission wavelength of 519 nm on a fluorescence-activated flow cytometer (FACSCalibur, 
Becton Dickinson, BD) and analysed with the BD CellQuest Pro software using a protocol  published 
previously (Cytlak et al. 2013).  Measurements were taken using a logarithmic gain. Forward scatter 
(FSC , size) and side scatter (SSC, granularity) gates for RBCs were identified in control experiments 
using anti-glycophorin A-PE labelled RBCs. The positive fluorescent gate was set using RBCs 
unlabelled with FITC-LA. For each measurement 10,000 events were gated. PS positive cells were 
defined as all events falling within the preset FSC, SSC and positive fluorescent gates. 
 
Statistics 
Results are mostly presented as means ± S.E.M., but ± S.D. in Figure 2, and as individual points in 
Figure 4b, of n observations in RBC samples taken from different individuals.  Where appropriate, 
comparisons were made using paired student t tests. When transport activities were measured over 
a range of oxygen tensions, t-tests followed by Holm-Šídák corrections for multiple comparisons 
were used (Graphpad Prism 6; CA, USA).  Correlations in Figure 3b were made using the Pearson 
correlation test.  The level of significance used was P < 0.05. 
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Results 
The effects of 5HMF on sickling in RBCs from SCD patients 
In the first series of experiments, the effects of 5HMF on sickling were confirmed (Figure 1).  In the 
absence of 5HMF, sickling in fully deoxygenated RBC approached about 80 % of the total, compared 
to about 10 % in fully oxygenated RBCs.  The latter is probably indicative of irreversibly sickled cells 
(ISCs) which sometimes accumulate in the circulation.  5HMF had no significant effect on percentage 
sickling at the two extremes of oxygen tension.  At intermediate oxygen tensions (10-40 mmHg), 
however, 5HMF reduced sickling by about 50 %, consistent with previous reports (Safo et al. 2004; 
Abdulmalik et al. 2005). 
 
The effect of 5HMF on volume of RBCs from SCD patients 
The effects of 5HMF on RBC volume were then addressed (Figure 2).  In fully oxygenated RBCs, RBC 
volume was unaffected by addition of 5HMF.  Under low oxygen tension (≤15 mmHg) RBC volume 
declined significantly in control RBCs.  By contrast in RBCs also incubated with 5HMF, volume was 
unchanged compared with those held under fully oxygenated conditions and was significantly 
increased above control RBCs lacking 5HMF.  The effect of cyclical deoxygenation / re-oxygenation 
was also tested.  In this case, the presence of 5HMF again produced an increase in RBC volume 
compared to RBCs incubated in its absence.  These effects of 5HMF would be consistent with 
inhibition of the cation efflux pathways which are upregulated in both oxygenated and 
deoxygenated RBCs from SCD patients (Lew & Bookchin 2005).  The mechanisms were therefore 
investigated further. 
 
The effect of 5HMF on the activity of Psickle in RBCs from SCD patients 
The non-specific deoxygenation-induced conductance termed Psickle is thought to be activated upon 
reduction of oxygen tension, HbS polymerisation and morphological sickling (Mohandas et al. 1986).  
Consistent with this postulate, 5HMF reduced Psickle activity (Figure 3a), with an inhibition of about 40 
% at 20 and 10 mmHg oxygen, and 15 % at 0 mmHg.  Sickling and Psickle activity correlated both in 
control RBCs (Pearson correlation r = 0.885, p < 0.0001) and those treated with 5HMF (r = 0.789, p < 
0.0001), as shown in Figure 3b. 
 
The effect of 5HMF on the activity of the Gardos channel in RBCs from SCD patients 
The Gardos channel is also activated by deoxygenation, HbS polymerisation and intracellular Ca2+ 
accumulation mediated probably via Psickle.  Reducing sickling and Psickle activity might be expected to 
inhibit the Gardos channel activity indirectly through reduction in Ca2+ entry.  This pattern was 
observed (Figure 4a).  Inhibition of deoxygenation-induced activation of the Gardos channel was 
about 70 % at 20 and 10 mmHg oxygen and 30 % at 0 mmHg, a larger effect than apparent with 
Psickle.  A possible direct effect of 5HMF on the Gardos channel independent of any effects on Ca
2+ 
entry was also tested.  In these experiments, RBCs were treated with A23187 and a free extracellular 
Ca2+ of 10 M (buffered with 2 mM EGTA) to produce near maximal activation of the Gardos 
channel.  K+ flux approached about 300 mmol.(l cells.h)-1 and some evidence of saturation of 86Rb+ 
accumulation was observed by about 7 min (Figure 4b).  The similarity of the K+ uptake curves in the 
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absence (filled symbols) and presence (open symbols) of 5HMF in ionophore-treated RBCs, however, 
argues against a direct effect of 5HMF on Gardos channel activity. 
 
The effect of 5HMF on deoxygenation-induced phosphatidylserine exposure in RBCs from SCD 
patients 
Ca2+ entry into RBCs following HbS polymerisation and activation of Psickle upon deoxygenation is also 
associated with increased externalisation of phosphatidylserine (PS) mediated via the Ca2+-
dependent scrambling process (Weiss et al. 2012; Cytlak et al. 2013).  Inhibition of Psickle, as well as 
inhibiting the Gardos channel, would be expected to reduce deoxygenation-induced PS exposure.  
This was investigated by incubating RBCs from SCD patients in 24-well plates whilst shaking in a 
hypoxic incubator (20 mmHg O2) over four hours.  Results are shown in Figure 5.  Deoxygenation 
increased PS exposure and externalisation was significantly reduced by treatment with 5HMF. 
 
The effect of 5HMF on activity of KCC in RBCs from SCD patients and normal individuals 
Unlike the situation in RBCs from normal individuals, in RBCs from SCD patients KCC activity is 
substantial and also observed in both oxygenated RBCs and following deoxygenation (Gibson et al. 
1998), probably reflecting differences in the regulatory pathways in RBCs from these two genotypes 
(Merciris et al. 2001).  KCC activity is shown in untreated RBCs from SCD patients and in the presence 
of 5HMF (Figure 6).  Under fully oxygenated conditions and also at oxygen tensions below the P50 for 
HbS, 5HMF produced a significant stimulation of KCC activity, although the magnitude of this effect 
declined with oxygen tension.  In fully deoxygenated RBCs, 5HMF had no significant effect on KCC 
activity. 
KCC activity is regulated by a cascade of protein kinase and phosphatase enzymes with increased 
activity associated with dephosphorylation of regulatory serine-threonine residues (Cossins et al. 
1994; Gibson & Ellory 2003).  The effect of 5HMF could therefore be mediated either directly on the 
transporter or indirectly via these regulatory enzymes.  These possibilities were investigated by pre-
treating RBCs with N-ethylmaleimide (NEM), an alkylating reagent which acts on –SH groups, and 
which activates KCC and prevents inhibition by inhibitors of protein phosphatases, together with any 
effect by modalities such as volume and oxygen tension which require their activity (Lauf 1983; 
Cossins et al. 1994).  As expected, KCC activity was elevated by treatment with 1 mM NEM (Figure 7).  
In the presence of NEM, addition of 5HMF produced a modest inhibition of KCC activity, in contrast 
to the stimulation observed in the absence of NEM treatment. 
KCC is also observed in oxygenated RBCs from normal individuals albeit at lower activities.  5HMF 
was therefore also tested in normal RBCs.  KCC activity in control conditions increased from 0.32 ± 
0.05 mmol.(l cells.h)-1 to 0.49 ± 0.07 (means ± S.E.M., n = 3, p < 0.02).  NEM also increased KCC 
activity in these RBCs but in this case addition of 5HMF had no significant effect. 
 
Dose dependence of 5HMF in RBCs from SCD patients 
Previous studies on HbS solutions, whole blood or in sickle transgenic mice in vivo have used 
concentrations of 5HMF in the low millimolar range (Safo et al. 2004; Abdulmalik et al. 2005), similar 
to the concentration of Hb in RBCs.  Dose dependence of 5HMF for increased O2 affinity and 
reduction of sickling in these previous studies indicate an IC50 of about 1 mM.  It is also important to 
establish whether lower concentrations of the reagent are effective on the transport pathways 
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studied here.  This was investigated in the experiments shown in Figure 8.  Significant levels of 
inhibition of Psickle, the Gardos channel and PS exposure were apparent at concentrations of 5HMF of 
1, 0.1 and 2 mM, respectively.  In these deoxygenated RBCs, stimulation of KCC was significant by 5 
mM.
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Discussion 
The present results demonstrate that 5HMF prevented dehydration of RBCs from SCD patients 
during maintained deoxygenation and during cyclical deoxygenation / re-oxygenation regimes.  
5HMF was further found to inhibit two of the main cation pathways which contribute to 
dehydration.  Thus as well as reducing morphological sickling in response to hypoxia, 5HMF inhibited 
both the deoxygenation-induced cation conductance (Psickle) and the Ca
2+-activated K+ channel (the 
Gardos channel), likely through inhibiting Psickle-mediated Ca
2+ entry.  Consistent with the latter, 
deoxygenation-induced phosphatidylserine (PS) exposure, associated with Ca2+ entry through Psickle, 
was also reduced.  The third pathway which participates in solute loss, the KCl cotransporter (KCC), 
was stimulated, probably through an effect on its regulatory phosphorylation cascade. 
5HMF is a naturally occurring five-membered heterocyclic aromatic aldehyde shown to interact 
allosterically with HbS to increase oxygen affinity and reduce sickling in vitro (Safo et al. 2004).  
5HMF combines with HbS to form high affinity Schiff bases, at least with the N-terminal α valine and 
probably at other additional sites (Safo et al. 2004).  5HMF is found in several food products such as 
honey as well as being present along with other furanic compounds in traditional Chinese medicines 
given for SCD (Rehmanniae Radix) (Lin et al. 2008).  Its low toxicity profile, better even than the 
aromatic aldehyde vanillin, makes it likely to be well tolerated in vivo.  In vivo experiments with a 
transgenic mouse model of SCD showed that 5HMF was found to have good pharmacokinetic 
properties (Abdulmalik et al. 2005).  As well as reducing RBC sickling, 5HMF also prolonged the 
survival time of these sickle mice under severe hypoxia.  Similar findings were later observed in non-
sickle mice under acute hypobaric hypoxia (Li et al. 2011).  5HMF appeared well tolerated in normal 
healthy volunteers also producing significant increases in Hb oxygen affinity (Stern et al. 2012).  It 
has now progressed to phase 2 clinical trials in patients with SCD (NIH 2013). 
The current results also demonstrate powerful effects on volume and K+ permeability of RBCs from 
SCD patients.  As expected from its morphological effects on sickling, 5HMF reduced activation of 
Psickle, a pathway thought to be activated by HbS polymerisation and the sickling shape change 
(Mohandas et al. 1986).  Psickle activity elevates intracellular Ca
2+ as well as depleting Mg2+ (Ortiz et al. 
1990; Rhoda et al. 1990; Willcocks et al. 2002).  That the Ca2+-activated K+ channel or Gardos channel 
activity was also inhibited by 5HMF is consistent with these effects, with its lack of effect following 
Ca2+ loading of RBCs with ionophore suggesting the absence of a direct action of 5HMF on the 
channel.  In a similar way, 5HMF also reduced deoxygenation-induced PS exposure, which is 
probably also mediated via Ca2+ entry and activation of the Ca2+-dependent scrambling process 
(Weiss et al. 2012; Cytlak et al. 2013).  These findings and the correlation between percentage 
sickling and Psickle activity (Figure 3) suggest that the main action of 5HMF on K
+ permeability would 
appear to be linked to its effects on HbS polymerisation.  These observations are consistent with the 
main effects of HbS on RBC cation permeability being mediated via its polymerisation (Mohandas et 
al. 1986).  A direct inhibitory effect of 5HMF on Psickle, however, cannot be excluded. 
The effects of 5HMF on KCC are more complicated.  In control RBCs, KCC activity was moderately 
increased and this effect was more evident at higher oxygen tensions.  Following treatment with 
NEM, by contrast, 5HMF was found to modestly inhibit transporter activity.  These findings are 
consistent with an action of 5HMF via the regulatory phosphorylation cascade which controls KCC 
activity (Cossins et al. 1994; Gibson & Ellory 2003).  It is possible that Mg2+ depletion, secondary to 
Psickle activity, may stimulate KCC through inhibition of protein phosphorlyation (Delpire & Lauf 1991; 
Muzyamba et al. 2006).  If this was the case, however, a stimulatory effect of 5HMF would be 
expected to be more pronounced following deoxygenation and this was not the case.  The exact 
mechanism by which 5HMF interacts with KCC requires further investigation.  In this context, it is 
worth noting that 5HMF was previously reported to be without effect on Na+ transport pathways 
(Na+/K+ pump, Na+/H+ exchange and Na+-K+-2Cl- cotransporter) (Safo et al. 2004). 
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The present results demonstrate a protective action of 5HMF against RBC dehydration under 
continuous hypoxia and also during cyclical deoxygenation / re-oxygenation.  By contrast, the 
insignificant effect of 5HMF on the volume of fully oxygenated RBCs suggests that even though KCC 
activity was probably increased, the effect was negligible.  It is worth pointing out that although KCC 
activity was increased by 5HMF, the absolute magnitude of the fluxes were relatively small. 
In conclusion, the hypothesis that 5HMF may reduce sickling through synergistic effects directly on 
HbS polymerisation and indirectly through reduction in solute loss and increased hydration appear 
valid.  The effect of 5HMF on K+ permeability and RBC volume would be useful measurements in 
clinical trials in SCD patients. 
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Figure legends 
Figure 1.  The effect of 5-hydroxymethyl-2-furfural (5HMF) on sickling of red blood cells (RBCs) from 
patients with sickle cell disease (SCD).  RBCs (15 % haematocrit, Hct) were pre-incubated with 5HMF 
(5 mM) for 30 min after which they were equilibrated in Eschweiler tonometers at the indicated 
oxygen tension for 20 min.  Aliquots were then fixed with glutaraldehyde and RBC shape assessed by 
light microscopy.  The percentage of sickled RBCs at each oxygen tension was normalised to that at 0 
mmHg O2 in the absence of 5HMF, which had a value of 84 ± 1.4% (range from 63 - 88%).  
Histograms represent means ± S.E.M., n = 6-7.  * p < 0.05 comparing control RBCs in the absence of 
5HMF with those incubated in its presence. 
Figure 2.  Effect of 5HMF on cell volume of RBCs from patients with SCD.  Cell volume was measured 
by wet weight – dry weight and expressed as ml water per g dry cell solids (ml.(g d.c.s.)-1) in RBCs 
maintained for 60 min under fully oxygenated conditions (Oxy), or under continual deoxygenation 
(≤15 mmHg O2), or under cycles of deoxygenation / re-oxygenation (Oxy / deoxy), in which oxygen 
tension was changed from 100 mmHg to 0 mmHg every 10 min.  Histograms represent means ± S.D., 
n = 3-7, and in all cases were paired experiments carried out in the absence and presence of 5HMF.  
# p < 0.05 comparing control oxygenated RBCs to control RBCs under the different deoxygenation 
protocols.  * p < 0.05 comparing deoxygenated RBCs in the absence of 5HMF with those incubated in 
its presence.  N.S. comparing oxygenated and deoxygenated RBCs in the presence of 5HMF. 
Figure 3.  Effect of 5HMF on the activity of Psickle in RBCs from patients with SCD.  RBCs were treated 
as described in the legend to Figure 1 except that after equilibration at different oxygen tensions in 
tonometers aliquots were diluted 10-fold into test tubes for measurement of K+ influx (calculated as 
mmol.(l cells.h)-1 and measured at an extracellular [K+] of 7.5 mM), all in the absence or presence of 
5HMF (5 mM).  Psickle is defined as the K
+ influx in Cl--free saline in the presence of ouabain (100 M), 
bumetanide (10 M) and clotrimazole (5 M).  (a) Activity of Psickle at each oxygen tension was 
normalised to that at 0 mmHg O2 in the absence of 5HMF, which had a value of 1.51 ± 0.27 mmol.(l 
cells.h)-1  (range from 0.66 - 2.45 mmol.(l cells.h)-1).  Histograms represent means ± S.E.M., n = 6-7.  * 
p < 0.05 comparing control RBCs in the absence of 5HMF with those incubated in its presence.  (b) 
Correlation of sickling and activity of Psickle in RBCs from patients with SCD.  Percentage sickling and 
activity of Psickle, from Figures 1 and 3a, both normalised to values in control RBCs at 0mmHg, were 
correlated in RBCs pre-incubated with 5HMF (5 mM) or handled similarly but in the absence of this 
heterocyclic aldehyde.  Pearson correlations were calculated as 0.885 in untreated RBCs (p < 0.0001) 
and 0.789 in the presence of 5HMF (p < 0.0001). 
Figure 4.  Effect of 5HMF on the activity of the Gardos channel in RBCs from patients with SCD.  (a) 
RBCs were treated as described in the legend to Figure 3a, all in the absence or presence of 5HMF (5 
mM).  Gardos channel activity is defined as the K+ influx (calculated as mmol.(l cells.h)-1 and 
measured at an extracellular [K+] of 7.5 mM) in the absence or presence of clotrimazole (5 M).  
Ouabain (100 M) and bumetanide (10 M) were included in all experiments. Activity of the Gardos 
channel at each oxygen tension was normalised to that at 0 mmHg O2 in the absence of 5HMF, which 
had a value of 3.1 ± 0.77 mmol.(l cells.h)-1 (range from 0.65 - 5.96 mmol.(l cells.h)-1).  Histograms 
represent means ± S.E.M., n = 6-7.  * p < 0.05 comparing control RBCs in the absence of 5HMF with 
those incubated in its presence.  (b) Effect of 5HMF on K+ uptake in Ca2+-loaded RBCs from patients 
with SCD.  Total K+ uptake (given as mmol.(l cells)-1 and measured at an extracellular [K+] of 80 mM) 
was measured over 10 min in RBCs treated with the ionophore A23187 (6 µM) in high K+-containing 
saline, at a free extracellular [Ca2+] of 10 µM (clamped with 2 mM EGTA), in the absence or presence 
of 5HMF (5 mM).  Under these conditions, K+ uptake in the absence of ionophore was < 0.5 mmol.(l 
cells)-1 over 10 min.  Ouabain (100 M) and bumetanide (10 M) were included in all experiments.  
Symbols represent paired data points from 4 different experiments, filled for controls in the absence 
of 5HMF, unfilled with 5HMF. 
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Figure 5.  Effect of 5HMF on phosphatidylserine exposure in RBCs from patients with SCD.  After a 60 
minute pre-incubation, RBC suspensions in Cl-MBS were deoxygenated (O2 of 20 mmHg) in shaken 
24-well plates in a low oxygen incubator for up to four hours in the absence and presence of 5HMF 
(5 mM).  Aliquots were removed at intervals and % RBCs positive for phosphatidylserine exposure 
measured using FACS.  Histograms represent means ± S.E.M., n = 4.  # p < 0.05 comparing control 
RBCs at time 0 and after 240 min.  * p < 0.05 comparing control RBCs in the absence of 5HMF with 
those incubated in its presence after 240 min.  
Figure 6.  Effect of 5HMF on the activity of the K+-Cl- cotransporter (KCC) in RBCs from patients with 
SCD.  RBCs were treated as described in the legend to Figure 3a, all in the presence or absence of 
5HMF (5 mM).  KCC activity is defined as the K+ influx (calculated as mmol.(l cells.h)-1 and measured 
at an extracellular [K+] of 7.5 mM) in the absence or presence of Cl- (substituted with NO3
-).  Ouabain 
(100 M), bumetanide (10 M) and clotrimazole (5 M) were included in all experiments.  Activity of 
KCC at each oxygen tension was normalised to that at 100 mmHg O2 in the absence of 5HMF, which 
had a value of 1.7 ± 0.31 mmol.(l cells.h)-1 (range from 0.56 - 2.54 mmol.(l cells.h)-1).  Histograms 
represent means ± S.E.M., n = 5-6.  * p < 0.05 comparing control RBCs in the absence of 5HMF with 
those incubated in its presence. 
Figure 7.  Effects of N-ethylmaleimide (NEM) and 5HMF on the activity of KCC in RBCs from patients 
with SCD.  RBCs were pre-incubated for 30 min with or without NEM (1 mM) and/or 5HMF (5 mM) 
after which they were diluted 10-fold into test tubes for measurement of K+ influx, all in the absence 
or presence of 5HMF (5 mM).  KCC activity is defined as the K+ influx (calculated as mmol.(l cells.h)-1 
and measured at an extracellular [K+] of 7.5 mM) in the absence or presence of Cl- (substituted with 
NO3
-)  Ouabain (100 M), bumetanide (10 M) and clotrimazole (5 M)  were included in all 
experiments.  Histograms represent means ± S.E.M., n = 5.  * p < 0.05 comparing RBCs in the 
absence and presence of 5HMF. 
Figure 8.  Dose dependence of 5HMF on the activities of Psickle, Gardos channel and KCC, and PS 
exposure in RBCs from patients with SCD.  To measure transport activities, RBCs were treated as 
described in the legends to Figures 3a, 4a and 6 with transport activity measured as mmol.(l cells.h)-
1) (at an extracellular [K+] of 7.5 mM) at 10mmHg O2.  PS exposure was measured as described in the 
legend to Figure 5 at 20mmHg O2.  Transport activities and PS exposure were normalised to that in 
the absence of 5HMF. Histograms represent means ± S.E.M., n = 4 for fluxes and n = 5 for PS 
exposure.  * p < 0.05 in RBCs incubated in the presence of 5HMF compared with its absence.
 20 
 
Figure 1 
 
 
0 10 20 40 100 
0
25
50
75
100 Control
5HMF
*
*
*
Oxygen tension (mmHg)
S
ic
k
li
n
g
 (
n
o
rm
a
li
s
e
d
)
 
 
 
 21 
 
Figure 2 
 
 
 
O
xy
15
 m
m
H
g
 O
xy
 / 
de
ox
y
0.0
1.2
1.4
1.6
1.8
2.0
**
#
N.S
Control
5HMF
V
o
lu
m
e
 i
n
 m
l.
(g
 d
.c
.s
)-
1
 
 
 
 22 
 
Figure 3a 
 
 
0 10 20 40 100 
0
25
50
75
100 Control
5HMF*
*
*
Oxygen tension (mmHg)
P
s
ic
k
le
 (
n
o
rm
a
li
s
e
d
)
 
 
 23 
 
Figure 3b 
 
0 25 50 75 100
0
25
50
75
100
Control
5HMF
Psickle - K
+ influx (normalised)
S
ic
k
li
n
g
 (
n
o
rm
a
li
s
e
d
)
 
 
 
 
 24 
 
Figure 4a 
 
 
0 10 20 40 100 
0
25
50
75
100 Control
5HMF
* *
*
Oxygen tension (mmHg)
G
a
rd
o
s
 (
n
o
rm
a
li
s
e
d
)
 
 
 
 25 
 
Figure 4b.   
 
0 2 4 6 8 10
0
10
20
30
40
50
Control
5HMF
Time (min)
G
a
rd
o
s
 (
m
m
o
l.
(l
 c
e
ll
s
)
-1
)
 
 
 26 
 
Figure 5 
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Figure 8 
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